Shares of ProVen VCT (LON:PVN - Get Free Report) reached a new 52-week low during trading on Friday . The stock traded as low as GBX 56.26 ($0.76) and last traded at GBX 59.26 ($0.80), with a volume of 8788316 shares changing hands. The stock had previously closed at GBX 59.50 ($0.81).
ProVen VCT Trading Down 0.4%
The firm's 50-day moving average price is GBX 59.13 and its 200 day moving average price is GBX 59.10. The company has a market capitalization of £161.22 million, a price-to-earnings ratio of 17.04 and a beta of 0.02.
ProVen VCT (LON:PVN - Get Free Report) last announced its quarterly earnings data on Monday, June 9th. The company reported GBX 0.20 ($0.00) earnings per share (EPS) for the quarter. ProVen VCT had a net margin of 67.04% and a return on equity of 5.22%.
ProVen VCT Company Profile
(
Get Free Report)
ProVen VCT plc is a venture capital trust specializing in emerging growth stage investment,expansion and management buyouts. The fund invests in small and medium sized smaller companies. It does not invest in startups. It seeks to invest in non-qualifying investments including cash, liquidity funds, fixed interest securities, debt and debt related securities in growth companies and non-qualifying venture capital investments.
Featured Articles
Before you consider ProVen VCT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProVen VCT wasn't on the list.
While ProVen VCT currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
